Federal Supply Schedule 36F79718D0405

Bristol-Myers Squibb Company was awarded an indefinite-delivery/indefinite-quantity contract under the Pharmaceuticals and Drugs Federal Supply Schedule master contract by the Department of Veterans Affairs Veterans Health Administration. The contract provides for the delivery of specialized oncology pharmaceuticals to various Veterans Integrated Service Networks.

Delivery orders issued against the contract to date have procured Bristol-Myers Squibb's BREYANZI and ABECMA treatments. BREYANZI is a chimeric antigen receptor T cell immunotherapy approved to treat adult patients with relapsed or refractory large B-cell lymphoma. ABECMA is a B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy. Delivery orders for these specialized cell therapies have been awarded to provide treatments within Veterans Integrated Service Networks 8, 12, and 19. The orders range in value from approximately $310,000 to $320,000, incorporate firm fixed pricing, and require performance at Bristol-Myers Squibb's Lawrenceville, New Jersey location. No set-aside provisions were applied under the contract or associated delivery orders awarded to date totaling over $2.5 million.